Compared with more common forms of AIH, APAH is characterized by an earlier onset of hepatitis and a lower positive rate for AIH-associated serum autoantibodies such as ANA, SMA, and LKM-1, as well as a more favorable response to immunomodulatory treatment. The gene discussed is BTG3; the disease is autoimmune hepatitis.